专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101730865B1 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법 有权
标题翻译：包含含瑞伐拉赞的纳米颗粒的口服给药用药物组合物及其制备方法
公开(公告)号：KR101730865B1
公开(公告)日：2017-04-27
申请号：KR1020110012426
申请日：2011-02-11
申请人： 주식회사유한양행
发明人： 김민수 , 김영훈 , 박명용
IPC分类号： A61K9/20 , A61K9/51 , A61K31/506
CPC分类号： A61K9/5138 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/5123 , A61K9/5161 , A61K31/506
摘要： 본발명은레바프라잔또는그의약학적으로허용가능한염; 특정양이온성고분자; 및유기산또는무기산을포함하는레바프라잔-함유나노입자를포함하는, 경구투여용약학조성물, 및그의제조방법을제공한다.
摘要翻译：本发明涉及包含瑞伐拉赞或其药学上可接受的盐的药物组合物; 特定阳离子聚合物以及含有有机酸或无机酸的含有瑞伐拉赞的纳米粒子及其制造方法。

2. 发明公开

KR1020130014376A 비스포스폰산 또는 그의 염을 함유하는 경구용 약학 조성물 无效
标题翻译：用于包含双磷酸盐或其盐的口服给药的药物组合物
公开(公告)号：KR1020130014376A
公开(公告)日：2013-02-07
申请号：KR1020120080787
申请日：2012-07-24
申请人： 주식회사유한양행
发明人： 김민수 , 심창용 , 박명용 , 주미경 , 강현우 , 노가야
IPC分类号： A61K31/675 , A61K31/663 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/00 , A61K9/14
CPC分类号： A61K9/0095 , A61K9/145 , A61K9/1635 , A61K9/1658 , A61K9/2027 , A61K9/2063 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K31/663 , A61K31/675
摘要： PURPOSE: An oral pharmaceutical composition containing bisphosphonic acid and an absorbing agent is provided to remarkably enhance the absorption of the bisphosphonic acid and a salt thereof into the human body and to minimize side effects. CONSTITUTION: An oral pharmaceutical composition contains bisphosphonic acid or a pharmaceutically acceptable salt thereof; and gelatin, polyvinyl acetal diethyl amino acetate; or a mixture thereof as an absorbing agent. The bisphosphonic acid is ibandronic acid, risedronic acid, alenronic acid, pamidronic acid, or zoledronic acid. The composition additionally contains citric acid, succinic acid, fumaric acid, acetic acid, phosphoric acid, sulfuric acid, or hydrochloric acid or inorganic acid. The composition also contains a surfactant or oil. [Reference numerals] (AA) Comparing formulation(Bonviva Tab.); (BB) Embodiment 11; (CC) Embodiment 12; (DD) Concentration of ibandronic acid in blood(ng/mL); (EE) Time(hr)
摘要翻译：目的：提供含有双膦酸和吸收剂的口服药物组合物，以显着增强双膦酸及其盐对人体的吸收并减少副作用。构成：口服药物组合物含有双膦酸或其药学上可接受的盐; 和明胶，聚乙烯醇缩醛二乙基氨基乙酸酯; 或其混合物作为吸收剂。双膦酸是伊班膦酸，利塞膦酸，阿仑膦酸，帕米膦酸或唑来膦酸。该组合物还含有柠檬酸，琥珀酸，富马酸，乙酸，磷酸，硫酸或盐酸或无机酸。该组合物还含有表面活性剂或油。（附图标记）（AA）比较配方（Bonviva Tab。）; （BB）实施例11; （CC）实施例12; （DD）血液中伊班膦酸浓度（ng / mL）; （EE）时间（小时）

3. 发明公开

KR1020120094178A 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법 有权
标题翻译：包含含有雷帕伐因的纳米颗粒的药物组合物及其制备方法
公开(公告)号：KR1020120094178A
公开(公告)日：2012-08-24
申请号：KR1020110012426
申请日：2011-02-11
申请人： 주식회사유한양행
发明人： 김민수 , 김영훈 , 박명용
IPC分类号： A61K9/20 , A61K9/51 , A61K31/506
CPC分类号： A61K9/5138 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/5123 , A61K9/5161 , A61K31/506
摘要： PURPOSE: A pharmaceutical composition for oral administration including revaprazan - containing nano-particles and a manufacturing method thereof are provided to reduce content of revaprazan or salt per unit dosage, thereby reducing the side effects. CONSTITUTION: A pharmaceutical composition for oral administration including revaprazan-containing nano-particles comprises revaprazan or salt which is allowable in pharmaceutical field, butyl methacrylate, copolymer of (2-dimethylaminoethyl)methacrylate and methyl methacrylate, polyvinylacetal, diethyleamino acetate or a polymer of a mixture thereof, and organic acid or inorganic acid. The composition has an average particle size of less than 1000 nano meters. A manufacturing method of the pharmaceutical composition for oral administration containing the revaprazan - containing nano-particles comprises the following steps: selectively dispersing revaprazan or pharmaceutically acceptable salt, a copolymer of butyl methacrylate, (2- dimethylaminoethyl) methacrylate and methylmethacrylate, and polyvinylacetal diethyleamino acetate or a mixture thereof, organic acid or inorganic acid, and surfactant in water; wet-grinding the dispersed solution which is obtained by dissolving a binder which is pharmaceutically acceptable into the dispersed solution; and drying the wet-grinded and dispersed solution with a binder, a diluent, a disintegrant, and a mixture thereof.
摘要翻译：目的：提供包含含雷帕拉唑的纳米粒子的口服药物组合物及其制造方法，以降低单位剂量的雷帕沙坦或盐的含量，从而减少副作用。构成：用于口服给药的药物组合物，包括含雷帕拉唑的纳米颗粒包括在药物领域中允许的雷帕沙或盐，甲基丙烯酸丁酯，（2-二甲基氨基乙基）甲基丙烯酸酯和甲基丙烯酸甲酯的共聚物，聚乙烯醇缩乙醛，二乙基氨基乙酸酯或其混合物，有机酸或无机酸。该组合物的平均粒径小于1000纳米。含有含雷帕拉唑的纳米粒子的口服药物组合物的制造方法包括以下步骤：选择性地分散雷帕拉坦或其药学上可接受的盐，甲基丙烯酸丁酯，（2-二甲基氨基乙基）甲基丙烯酸甲酯和甲基丙烯酸甲酯的共聚物，以及聚乙烯醇缩乙醛二乙基氨基乙酸酯或其混合物，有机酸或无机酸和表面活性剂在水中; 湿式研磨通过将药学上可接受的粘合剂溶解在分散溶液中而获得的分散溶液; 并用粘合剂，稀释剂，崩解剂及其混合物干燥湿研磨和分散的溶液。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式